The contentious case underscores just how important scientific papers are to launching and sustaining a researcher's career.February 9, 2024Check out STAT+Sponsored By Running February 2–13, 2024: Get 3 months of STAT+ for $20 for World Cancer Day. Subscribe now to get unlimited access to must-read news about cancer research. Photo illustration: STAT; Photo: Adobe STAT+ | A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit An early-career kidney researcher accuses Padmanee Sharma at MD Anderson of derailing her career after dispute over study authorship. By Angus Chen and Jonathan Wosen STAT+ | A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys Adam Feuerstein previews the expected readout from Gritstone Bio's neoantigen cancer vaccine study, and discusses the Novartis-MorphoSys deal. By Adam Feuerstein STAT+ | Why Novartis is going to walk away from its acquisition of MorphoSys The Swiss drug giant will be happy to pay a small breakup fee to MorphoSys to avoid owning a drug that regulators will turn away. By Adam Feuerstein FABRICE COFFRINI/AFP/Getty Images STAT+ | Novartis to buy German biotech MorphoSys for $2.9 billion At the center of the deal is pelabresib, a blood cancer pill that in November posted mixed results in a Phase 3 trial. By Jason Mast More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments